Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome®) in beagle dogs

Pharmaceutical Research

Volumn 16, Issue 11, 1999, Pages 1694-1701

  Bekersky, Ihor ^a   Boswell, Garry W ^b   Hiles, Richard ^c   Fielding, Robert M ^d   Buell, Donald ^a   Walsh, Thomas J ^e  

^a ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^b MDS Inc   (Canada)

^c AMYLIN PHARMACEUTICALS INC   (United States)

^d Biologistic Services Boulder   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Amphotericin B; Liposomes; Pharmacokinetics; Tissue distribution; Toxicity; Toxicokinetics

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ANIMAL EXPERIMENT; ARTICLE; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SAFETY; DRUG UPTAKE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TUBULE NECROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; TOXICITY TESTING;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; BLOOD CELL COUNT; BODY WEIGHT; DOGS; FEMALE; INFUSIONS, INTRAVENOUS; KIDNEY; LIPOSOMES; MALE; RANDOM ALLOCATION; TIME FACTORS; TISSUE DISTRIBUTION; URINALYSIS;

EID: 0032708527     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018997730462     Document Type: Article

References (24)

1. 1. J. E. Bennett. Antimicrobial Agents: Antifungal Agents. In J. G. Hardman and L. E. Limbird (eds.), Goodman & Gilman's the Pharmacological Basis of Therapeutics, 9th ed., McGraw-Hill, New York, 1996, Ch. 49.
2. 2. D. B. Bhathena, W. E. Bullock, C. E. Nuttall, and R. G. Luke. The effects of amphotericin B therapy on the intrarenal vasculature and renal tubules in man. Clin. Nephrol. 9:103-110 (1978).
3. 3. I. Bekersky, R. M. Fielding, D. Buell, and I. Lawrence. Lipid-based amphotericin B formulations: from animals to man. Pharmaceut. Sci. Technol. Today 2:230-236 (1999).
4. 4. R. M. Fielding, A. W. Singer, L. H. Wang, S. Babbar, and L. S. S. Guo. Relationship of pharmacokinetics and tissue distribution to reduced toxicity of colloidal amphotericin B in dogs. Antimicrob. Agents Chemother. 36:299-307 (1992)
5. 5. G. Lopez-Berestein, R. Mehta, R. L. Hopfer, et al. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome encapsulated amphotericin B. J. Infect. Dis. 147:939-945 (1983).
6. 6. J. Graybill, P. Craven, R. Taylor, D. Williams, and W. Magee. Treatment of murine cryptococcosis with liposome-associated amphotericin B. J. Infect. Dis. 145:748-752 (1982).
7. 7. C. Tremblay, M. Barza, C. Fiore, and F. Szoka. Efficacy of liposome intercalated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob. Agents Chemother. 26:170-17 (1984).
8. 8. K. M. Wasan, A. L. Kennedy, S. M. Cassidy, et al. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies. Antimicrob. Agents Chemother. 42:3146-3152 (1998).
9. 9. J. P. Sculier, A. Coune, F. Meunier, et al. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur. J. Cancer Clin. Oncol. 24:527-538 (1988).
10. 10. G. Lopez-Berestein, V. Fainstein, R. Hopfer, et al. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: A preliminary study. J. Infect. Dis. 151:704-710 (1985).
11. 11. R. P. Rapp, P. O. Gubbins, and M. E. Evans. Amphotericin B lipid complex. Ann. Pharmacother. 31:1174-86 (1997).
12. 12. R. T. Proffitt, A. Satorius, S.-M. Chiang, et al. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J. Antimicrob. Chemother. 28 (Suppl. B):49-61 (1991).
13. 13. J. P. Adler-Moore, S.-M. Chiang, A. Satorius, et al. Treatment of murine candidosis and ctyptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). J. Antimicrob. Chemother. 28 (Suppl. B):63-71 (1991).
14. 14. K. V. Clemons and D. A. Stevens. Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. J. Antimicrob. Chemother. 32:465-472 (1993).
15. 15. T. J. Walsh, V. Yeldandi, M. McEvoy, et al. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob. Agents Chemother. 42:2391-2398 (1998).
16. 16. T. J. Walsh, R. W. Finberg, C. Arndt, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. New Engl. J. Med. 340:764 (1999).
17. 17. A. J. Coukell and R. N. Brogden. Liposomal amphotericin B: Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 55:585-612 (1998).
18. 18. R. Janknegt, S. deMarie, I. A. J. M. Bakker-Woudenberg, et al. Liposomal and lipid formulations of amphotericin B: clinical pharmacokinetics. Clin. Pharmacokinet. 23:279-291 (1992).
19. 19. A. Alak, S. Moys, and I. Bekersky. A high-performance liquid chromatographic assay for the determination of amphotericin B serum concentrations after the administration of AmBisome, a liposomal amphotericin B formulation. Ther. Drug Monit. 18:604-609 (1996).
20. 20. R. M. Fielding, G. Mukwaya, and R. A. Sandhaus. Clinical and preclinical studies with low-clearance liposomal Amikacin (MiKasome®). In M. C. Woodle and G. Storm (eds.), Long-Circulating Liposomes: Old Drugs, New Therapeutics, Springer-Verlag, New York, 1998, Ch. 15.
21. 21. P. D. Hoeprich, A. C. Huston, and B. M. Wolfe. Toxicity of Amphotericins on Chronic Administration to Mongrel Dogs. Diagn. Microbiol. Infect. Dis. 3:47-58 (1985).
22. 22. J. P. Adler-Moore and R. T. Proffitt. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J. Liposome Res. 3:429-450 (1993).
23. 23. G. W. Boswell, I. Bekersky, D. Buell, R. Hiles, and T. J. Walsh. Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats. Antimicrob. Agents Chemother. 42:263-268 (1998).
24. 24. H. Harashima and H. Kiwada. Liposomal targeting and drug delivery: kinetic consideration. Adv. Drug Del. Rev. 19:425-444 (1996).